A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 15, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-07-11
DOI
10.1186/s13045-022-01309-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
- (2021) Hagop M. Kantarjian et al. LEUKEMIA
- Global, Regional, and National Burden of Chronic Myeloid Leukemia, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017
- (2021) Qingqing Lin et al. Frontiers in Oncology
- SOCIAL AND FINANCIAL BARRIERS TO OPTIMUM TKI TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA- A KNOWLEDGE-ATTITUDES-PRACTICES STUDY FROM INDIA
- (2021) Naveen Gupta et al. Mediterranean Journal of Hematology and Infectious Diseases
- Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial
- (2021) Jerald P. Radich et al. LEUKEMIA
- Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia
- (2021) Massimo Breccia et al. Frontiers in Oncology
- Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial
- (2021) Jorge Cortes et al. BLOOD
- A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs
- (2021) Delphine Rea et al. BLOOD
- OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON).
- (2021) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia.
- (2021) Tim H. Brümmendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient-Reported Functional Outcomes in Patients with Chronic Myeloid Leukemia after Stopping Tyrosine Kinase Inhibitors
- (2021) Kelly L Schoenbeck et al. JNCI-Journal of the National Cancer Institute
- The Care of the Leukemic Patients in Times of SARS-CoV-2
- (2021) Nabin Raj Karki et al. Current Oncology Reports
- Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial
- (2021) Massimo Breccia et al. BLOOD
- Identification of Immunological Parameters Related to Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission
- (2020) Valentín Garcia-Gutiérrez et al. BLOOD
- An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia
- (2020) Qian Jiang et al. BLOOD
- Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)
- (2020) Young Rok Do et al. BRITISH JOURNAL OF HAEMATOLOGY
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
- (2020) A. Hochhaus et al. LEUKEMIA
- Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia
- (2020) Hsiao Ling Phuar et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study
- (2020) Dragana Milojkovic et al. BRITISH JOURNAL OF HAEMATOLOGY
- Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
- (2020) Jorge E. Cortes et al. LEUKEMIA
- How many chronic myeloid leukemia patients who started a frontline second‐generation tyrosine kinase inhibitor have to switch to a second‐line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA)
- (2020) Massimo Breccia et al. Cancer Medicine
- Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
- (2020) Christel C. L. M. Boons et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission
- (2020) Philippe Rousselot et al. Blood Advances
- Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase 3, Randomized, Open-label, Multi-center FESTnd Study
- (2020) Li Zhang et al. CLINICAL CANCER RESEARCH
- The EUTOS long‐term survival score predicts disease‐specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice‐based cohort
- (2020) Eriko Sato et al. Cancer Medicine
- Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2
- (2020) Sara Galimberti et al. Frontiers in Oncology
- Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs
- (2020) Andreas Hochhaus et al. BLOOD
- Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission
- (2020) Lorena Vigón et al. Journal of Clinical Medicine
- Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
- (2019) Kamal Chamoun et al. Journal of Hematology & Oncology
- The potential health gain and cost savings of improving adherence in chronic myeloid leukemia
- (2019) Geneviève I.C.G. Ector et al. LEUKEMIA & LYMPHOMA
- De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial
- (2019) Richard E Clark et al. Lancet Haematology
- Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
- (2019) Christopher A. Eide et al. CANCER CELL
- BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia
- (2019) Orlando Antelope et al. EXPERIMENTAL HEMATOLOGY
- Digital droplet PCR at the time of TKI discontinuation in chronic‐phase chronic myeloid leukemia patients is predictive of treatment‐free remission outcome
- (2019) Gioia Colafigli et al. HEMATOLOGICAL ONCOLOGY
- PF-114: A 4th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1T315I
- (2019) Anna G. Turkina et al. BLOOD
- Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial
- (2019) Massimo Breccia et al. BLOOD
- Sudden blastic transformation in treatment‐free remission chronic myeloid leukaemia
- (2019) Mansour Alfayez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
- (2019) Neil P. Shah et al. LEUKEMIA & LYMPHOMA
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
- (2019) Timothy P. Hughes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase
- (2018) François-Xavier Mahon et al. ANNALS OF INTERNAL MEDICINE
- Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
- (2018) Jorge E. Cortes et al. BLOOD
- Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment
- (2018) Masaya Okada et al. Clinical Lymphoma Myeloma & Leukemia
- Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression
- (2018) Wen-Jun Wang et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
- (2018) David M. Ross et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
- (2018) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
- (2018) Susanne Saussele et al. LANCET ONCOLOGY
- The rising prevalence of chronic myeloid leukemia in France
- (2018) Marc Delord et al. LEUKEMIA RESEARCH
- Chronic Myeloid Leukemia: Long-Term Outcome Data in the Imatinib Era
- (2018) Prasanth Ganesan et al. INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
- Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up.
- (2018) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY
- (2018) Rüdiger Hehlmann et al. AMERICAN JOURNAL OF HEMATOLOGY
- Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries
- (2017) Jan Geissler et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
- (2017) Gabriel Etienne et al. JOURNAL OF CLINICAL ONCOLOGY
- The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
- (2017) Andrew A. Wylie et al. NATURE
- Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
- (2016) Delphine Rea et al. BLOOD
- Epidemiology of Obesity and Diabetes and Their Cardiovascular Complications
- (2016) Shilpa N. Bhupathiraju et al. CIRCULATION RESEARCH
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- (2016) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
- (2016) Hannah Bower et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
- (2016) A Hochhaus et al. LEUKEMIA
- Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial
- (2016) Jorge E Cortes et al. Lancet Haematology
- Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study
- (2015) Silvia Mori et al. AMERICAN JOURNAL OF HEMATOLOGY
- Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV
- (2015) S. Saussele et al. BLOOD
- Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1
- (2015) M S Zabriskie et al. LEUKEMIA
- Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
- (2015) Koji Sasaki et al. Lancet Haematology
- Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges
- (2014) L. Noens et al. HAEMATOLOGICA
- PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation
- (2014) A A Mian et al. LEUKEMIA
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
- (2013) T. P. Hughes et al. BLOOD
- Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
- (2013) D. M. Ross et al. BLOOD
- Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib
- (2013) Massimo Breccia et al. CANCER LETTERS
- Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
- (2013) Stacie B. Dusetzina et al. JOURNAL OF CLINICAL ONCOLOGY
- Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib
- (2013) Alfonso Quintás-Cardama et al. LEUKEMIA RESEARCH
- Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) M. Baccarani et al. ANNALS OF ONCOLOGY
- Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
- (2012) H. Kantarjian et al. BLOOD
- Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy
- (2012) N. Pemmaraju et al. HAEMATOLOGICA
- Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
- (2010) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
- (2009) A. Quintas-Cardama et al. BLOOD
- Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients
- (2009) Eric Q. Wu et al. CURRENT MEDICAL RESEARCH AND OPINION
- Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis
- (2008) Hugues de Lavallade et al. BRITISH JOURNAL OF HAEMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started